Alzheimer’s science has undergone a paradigm shift toward the disease’s silent phase. For trials, this means change at every level: new participants, new screening tools, new outcome measurements. What’s the progress?
Clinical validation is showing automated Elecsys, Lumipulse assays to be reliable and predictive. The story on blood tests has turned from non-starter to intensely promising for broad-based screening.
Certified reference material by which companies can calibrate assays is now available worldwide.
An infrared spectral signature of amyloid β-sheets predicted AD conversion years before diagnosis.
High vascular risk scores and Aβ burden independently associate with cognitive decline, but combined, they speed things up.
Investors pledge new money for research into biomarkers that yield marketable tests.
Sensitive cognitive tests detect deficits in preclinical Alzheimer’s even before an amyloid scan reads positive. And CSF Aβ42 drops a decade before that—pushing research ever farther into the preclinical phase.
Where does TREM2-dependent microglial activity fit into the staging diagram of Alzheimer’s disease?
TREM2 levels tracked with tau, but varied widely among patients and carriers of different mutations, leaving it unclear whether TREM2 helps or hurts.
Probing this this Alzheimer’s risk factor, scientists find a novel variant, but no consensus yet on how this cell surface receptor increases risk for disease.
For the first time, scientists report a crystal structure of TSPO, a potential target for PET imaging of neuroinflammation.
Hoping for better luck in clinical trials than their Alzheimer’s colleagues had in the past decade, FTD researchers are now chasing biomarkers. It’s slim pickings so far, but neurofilament, tau PET, and MRI are showing promise.
Study improves confidence in three core biomarkers and five emerging markers, most in cerebrospinal fluid and one in blood.
Can proteins in the cerebrospinal fluid help tell movement disorders apart and predict who will develop dementia?
Identifying injuries that might lead to chronic traumatic encephalopathy or other neurodegenerative pathologies, and then treating those injuries, are two major challenges...